This post was originally published on this site
Canopy Growth Corp. said Monday it has named David Klein, currently chief financial officer at its biggest shareholder, Constellation Brands Inc., as its new chief executive, taking over from Mark Zekulin on January 14.
The news sent the U.S.-listed shares up about 12% in early trade.
Zekulin became the sole CEO of the largest cannabis company by market capitalization after the Constellation Brands-dominated board of directors fired former co-CEO Bruce Linton in July. Zekulin and Linton previously told MarketWatch that tensions in the boardroom had been rising in the months after Constellation STZ, -1.54% took control of the Canopy CGC, +13.54% WEED, +12.22% board as part of a $4 billion investment.
Prior to Linton’s dismissal, Zekulin -—a one-time political operative—- held the title of co-CEO and was largely responsible for the company’s day-to-day operations, while Linton operated as a public-facing spokesman and liaison to the capital markets. When the board ousted Linton, Zekulin agreed to remain as the sole CEO until a replacement was found, presiding over two-plus quarters of lackluster earnings amid broad problems for Canadian weed companies.
Zekulin previously told MarketWatch that there was a short list of replacement CEO candidates and that he and the board aimed to find an appropriate choice by the end of the year.
Klein has been at Corona beer brewer Constellation for 14 years. In his current role as CFO and executive vice president, he has overseen the company’s finance operations, M&A activity and IT. he has sat on the Canopy board for the past year and is current its chair. The company is planning to appoint a new chair once Klein takes up his new role.
Jefferie’s analyst Owen Bennett said the news was mixed.
“Positive views (are) likely to be taken around implications for greater financial focus and commitment from Constellation Brands, though also negatives around potential lack of external appetite for the role, and the likelihood of a heavy focus on an unproven beverage category,” he wrote in a note to clients. “Expect financials to continue to underwhelm as domestic Canada struggles continue.”
Read now: All the excuses cannabis companies are making for an ugly crop of earnings
The Canadian cannabis sector has suffered a prolonged stock slump in the past few months, as the rollout of legal cannabis has advanced far more slowly than expected. Companies have been hurt by a shortage of retail outlets as licensing is hampered by regulations that have allowed the black market to thrive. As a result, revenue has not lived up to expectations and most companies continue to post heavy losses.
See now: Canopy Growth CEO defends ugly quarter as one-time event
Canopy has been gearing up for the launch of Cannabis 2.0 in Canada, the name given to the launch of cannabis derivatives such as edibles and beverages that is set to start in early 2020. Prior to November, only flower and oil were legal in Canada.
The company’s portfolio of products for Cannabis 2.0 will include chocolates, vape cartridges and pens and distilled cannabis drinks.
Don’t miss: ‘CBD has the potential to harm you,’ FDA warns consumers
Related: Cannabis stocks rocked as FDA warning undermines case for CBD investments
Canopy is developing a line of Tweed-branded drinks with 2 mg of THC per can, as well as Houseplant Grapefruit and Houseplant Lemon drinks that are part of a partnership with actor Seth Rogen and screenwriter and producer Evan Goldberg. Those drinks will contain 2.5 mg of THC per 355 mL can.
Read also: Canopy Growth will not be profitable by fiscal 2022, according to this analyst
The company is also planning seltzer-like sparkling water products under the new brand Quatreau, that will contain 20 mg of CBD or 2 mg CBD and 2 mg THC per can. For consumers looking for a more potent drink, the company is developing a brand of mixers that will be packaged in 150 mln bottles using its propriety clear liquid cannabis.
Canopy shares have fallen 22% in 2019, while the ETFMG Alternative Harvest ETF MJ, +2.39% has fallen 31% and the S&P 500 SPX, +0.01% has gained 25%.
Cannabis Watch: Click here for all of MarketWatch’s coverage of cannabis companies
